Abstract
Radioiodine is commonly used to treat differentiated thyroid carcinoma. Nonetheless, the high activities administered during therapy are potentially carcinogenic for other organs, such as the salivary glands and digestive tract. The risk of second primary malignancies after radioiodine therapy for thyroid carcinoma is discussed by the author of this Viewpoint.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nature Clinical Practice Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
